Please login to the form below

Not currently logged in
Email:
Password:

larotrectinib

This page shows the latest larotrectinib news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology, personalised medicine continues to drive pharma sector

Immuno-oncology, personalised medicine continues to drive pharma sector

A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was

Latest news

More from news
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Vitrakvi(larotrectinib) gained FDA approval in late November to treat any solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, which causes the production of TRK, a family ... In Europe, a marketing application for

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    also extending to targeted cancer drugs, with Loxo Oncology and Bayer’s larotrectinib filed for TRK gene fusion tumours and due for an FDA verdict in November.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics